Minerva Neurosciences (NERV) Return on Capital Employed (2014 - 2026)
Minerva Neurosciences (NERV) posted Return on Capital Employed of 30.46% for Q1 2026, down 22.48% on a QoQ basis from 24.86% in Q4 2025, and up 2729.0% year-over-year from 1.08% in Q1 2025.
Minerva Neurosciences (NERV) Return on Capital Employed (2014 - 2026) Analysis & Trends
Minerva Neurosciences' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 30.46% for Q1 2026.
- Quarterly Return on Capital Employed rose 2729.0% year-over-year to 30.46% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 30.46% (up 2729.0% YoY) and the FY2025 annual result came in at 23.14%, up 2631.0% from the prior year.
- Return on Capital Employed was 30.46% for Q1 2026 at Minerva Neurosciences, down from 24.86% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 24.86% in Q4 2025 and bottomed at 69.04% in Q3 2022.
- A 5-year average of 50.15% and a median of 55.09% in 2025 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2022 — Return on Capital Employed plunged 7304 bps — and 2023, when it surged 3503 bps.
- Minerva Neurosciences' Return on Capital Employed stood at 45.02% in 2022, then climbed by 9 bps to 40.79% in 2023, then plunged by 44 bps to 58.83% in 2024, then surged by 58 bps to 24.86% in 2025, then declined by 22 bps to 30.46% in 2026.
- Business Quant data shows NERV's Return on Capital Employed at 30.46% in Q1 2026, 24.86% in Q4 2025, and 55.09% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -30.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -30.46% |
| Dec 31, 2025 | -24.86% |
| Sep 30, 2025 | -55.09% |
| Jun 30, 2025 | -55.59% |
| Mar 31, 2025 | -57.74% |
| Dec 31, 2024 | -58.83% |
| Sep 30, 2024 | -61.14% |
| Jun 30, 2024 | -59.30% |
| Mar 31, 2024 | -48.07% |
| Dec 31, 2023 | -40.79% |
| Sep 30, 2023 | -34.02% |
| Jun 30, 2023 | -35.06% |
| Mar 31, 2023 | -44.44% |
| Dec 31, 2022 | -45.02% |
| Sep 30, 2022 | -69.04% |
| Jun 30, 2022 | -68.11% |
| Mar 31, 2022 | -64.92% |
| Dec 31, 2021 | -53.67% |
| Sep 30, 2021 | -31.81% |
| Jun 30, 2021 | -30.60% |